WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

14.07.2016: WILEX publishes Half-yearly Financial Report: WILEX AG today published its financial report on the first six months of 2016 (1 December 2015 - 31 May 2016). ...More

 

 

 

Seite gelesen: 557678 | Heute: 327